investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Extraordinary responder cell lines reveal unique targetable genetic dependencies
Hugh S. Gannon
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Hugh S. Gannon
Dana-Farber Cancer Institute
Boston, United States
Related projects
Arunasree Kalle
Study the Methylation and Acetylation Status of Xi and Xa Chromosome in Normal and Cancerous Breast Epithelial Cells
Breast
Matthew P Goetz
Mayo Clinic Breast Cancer SPORE
Breast
Pathology
Ajit P Varki
Oligosaccharies of Normal and Malignant Cells
Breast
Fariba Behbod
Elucidating Cellular Heterogeneity Among Cancer Stem Cells by Raman Spectroscopy
Breast
Radiation Oncology
Sergey Korolev
Structural and Functional Studies of Tumor Suppressor Proteins PALB2 and BRCA2
Breast
Eun-Sil S Hwang
(PQC3) Genomic Diversity and Microenvironment as Drivers of Metastasis in DCIS
Breast
Richard A Anderson
PI Signaling Role in Epithelial/Mesenchymal Transition
Breast
Dimitar B Nikolov
Function-blocking anti-ADAM protease antibodies for inhibition of tumorigenesis - NY
Breast
Powel Brown
VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST
Breast